Relapsing Multiple Sclerosis (RMS): Clinical Trials

1 completed, 1 terminated. 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	2	Completed 1, Terminated 1

Follow Relapsing Multiple Sclerosis (RMS): new trials by email Literature Review of Relapsing Multiple Sclerosis (RMS) trials Research Report on Relapsing Multiple Sclerosis (RMS)

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS)	Phase 4	Terminated	Novartis Pharmaceuticals	24	2021-06-10	2025-05-16
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients Fingolimod 0.5mg - Relapsing Multiple Sclerosis (RMS)	Phase 4	Completed	Novartis Pharmaceuticals	98	2021-02-20	2026-01-13

Narrower conditions

COVID-19 (1)  ·  Coronavirus Infections (1)  ·  Multiple Sclerosis (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Coronaviridae Infections (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Infections (1)  ·  Lung Diseases (1)  ·  Nervous System Diseases (1)  ·  Nidovirales Infections (1)  ·  Pneumonia (1)  ·  Pneumonia, Viral (1)  ·  RNA Virus Infections (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Infections (1)

Interventions

CVnCoV COVID-19 vaccine (1)  ·  Fingolimod Hydrochloride (1)  ·  Glatiramer Acetate (1)  ·  Interferons (1)  ·  ofatumumab (1)

Sponsors

Novartis Pharmaceuticals (2)

Countries

China (1)  ·  United States (1)